Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 4/2019

01-11-2019 | Kawasaki Disease | Original Article

Increased levels of circulating fibroblast growth factor 21 in children with Kawasaki disease

Authors: Yue Peng, Qiongfei Pei, Siqi Feng, Ya Su, Ruixi Liu, Qijian Yi, Pengfei Guo

Published in: Clinical and Experimental Medicine | Issue 4/2019

Login to get access

Abstract

The purpose of this study was to examine the serum levels of fibroblast growth factor 21 (FGF21) in children with acute Kawasaki disease (KD) and to investigate its relationship with coronary artery lesions (CALs). Blood samples from 58 children with KD before intravenous immunoglobulin treatment and from 28 healthy children as control group were collected. Serum FGF21 levels in all participants were measured using enzyme-linked immunosorbent assay, and clinical parameters were tested in all KD patients. Serum FGF21 levels were significantly increased in acute KD patients as compared to the control group. Serum levels of FGF21 were substantially higher in the group of KD patients with CALs (KD-CALs) than in KD patients without CALs (KD-NCALs). Positive relationships between serum levels of FGF21 and percentage of leukomonocytes (L %), C-reactive protein, activated partial thromboplastin time and D-dimer were observed in KD patients. Furthermore, serum FGF21 levels were negatively correlated with red blood cell counts, hemoglobin (Hb), percentage of neutrophils (N %) and albumin. Serum level of FGF21 is associated with inflammation and coagulation. The paradoxical increase in serum FGF21 in acute KD patients may indicate a protective compensatory response.
Literature
1.
Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn. 1991;41(11):785–97.PubMed
2.
Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94(6):1379–85.PubMedCrossRef
3.
Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40(1):35–42.PubMedCrossRef
4.
Shimizu C, Jain S, Davila S, et al. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet. 2011;4(1):16–25.PubMedCrossRef
5.
6.
Yoshida LS, Tsunawaki S. Expression of NADPH oxidases and enhanced H(2)O(2)-generating activity in human coronary artery endothelial cells upon induction with tumor necrosis factor-alpha. Int Immunopharmacol. 2008;8(10):1377–85.PubMedCrossRef
7.
Miura M, Garcia FL, Crawford SE, Rowley AH. Cell adhesion molecule expression in coronary artery aneurysms in acute Kawasaki disease. Pediatr Infect Dis J. 2004;23(10):931–6.PubMedCrossRef
8.
Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol. 2005;141(3):381–7.PubMedPubMedCentralCrossRef
9.
Lago F, Dieguez C, Gómez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev. 2007;18(3–4):313–25.PubMedCrossRef
10.
Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta. 2004;344(1–2):1–12.PubMedCrossRef
11.
Mocan Hognogi LD, Goidescu CM, Farcaş AD. Usefulness of the adipokines as biomarkers of ischemic cardiac dysfunction. Dis Mark. 2018;2018:3406028.
12.
Jose VJ, Mariappan P, George PV, Selvakumar D. Serum leptin levels in acute myocardial infarction. Indian Heart J. 2005;57(1):39–43.PubMed
13.
14.
Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol. 2007;27(9):3417–28.PubMedPubMedCentralCrossRef
15.
Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res. 2010;342(1):1–11.PubMedPubMedCentralCrossRef
16.
Kokkinos J, Tang S, Rye KA, Ong KL. The role of fibroblast growth factor 21 in atherosclerosis. Atherosclerosis. 2017;257:259–65.PubMedCrossRef
17.
Tanajak P, Chattipakorn SC, Chattipakorn N. Effects of fibroblast growth factor 21 on the heart. J Endocrinol. 2015;227(2):R13–30.PubMedCrossRef
18.
Lin Z, Tian H, Lam KS, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17(5):779–89.PubMedCrossRef
19.
Liu R, He B, Gao F, Liu Q, Yi Q. Relationship between adipokines and coronary artery aneurysm in children with Kawasaki disease. Transl Res. 2012;160(2):131–6.PubMedCrossRef
20.
Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47(2):232–4.PubMedCrossRef
21.
Manlhiot C, Millar K, Golding F, et al. Improved classification of coronary artery abnormalities based only on coronary artery Z-scores after Kawasaki disease. Pediatr Cardiol. 2010;31(2):242–9.PubMedCrossRef
22.
Iglesias P, Selgas R, Romero S, Díez JJ. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol. 2012;167(3):301–9.PubMedCrossRef
23.
Roth J, Szulc AL, Danoff A. Energy, evolution, and human diseases: an overview. Am J Clin Nutr. 2011;93(4):875S–83S.PubMedCrossRef
24.
Wang XM, Song SS, Xiao H, Gao P, Li XJ, Si LY. Fibroblast growth factor 21 protects against high glucose induced cellular damage and dysfunction of endothelial nitric-oxide synthase in endothelial cells. Cell Physiol Biochem. 2014;34(3):658–71.PubMedCrossRef
25.
Zhu W, Wang C, Liu L, et al. Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo. Can J Physiol Pharmacol. 2014;92(11):927–35.PubMedCrossRef
26.
Miyazaki Y, Saita E, Kishimoto Y, et al. Low plasma levels of fibroblast growth factor-21 in patients with peripheral artery disease. J Atheroscler Thromb. 2018;25(9):821–8.PubMedPubMedCentralCrossRef
27.
Pipatpiboon N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. PPARγ agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology. 2012;153(1):329–38.PubMedCrossRef
28.
Cheng J, Su X, Qiao L, Zhai C, Chen W. Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris. Biosci Rep. 2018;38(5):1.
29.
Yu Y, He J, Li S, et al. Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway. Int Immunopharmacol. 2016;38:144–52.PubMedCrossRef
30.
Bell DM, Brink EW, Nitzkin JL, et al. Kawasaki syndrome: description of two outbreaks in the United States. N Engl J Med. 1981;304(26):1568–75.PubMedCrossRef
31.
Nigro G, Zerbini M, Krzysztofiak A, et al. Active or recent parvovirus B19 infection in children with Kawasaki disease. Lancet. 1994;343(8908):1260–1.PubMedCrossRef
32.
Li JY, Wang N, Khoso MH, et al. FGF-21 elevated IL-10 production to correct LPS-induced inflammation. Inflammation. 2018;41(3):751–9.PubMedCrossRef
33.
Kim EK, Lee Sh, Jhun JY, et al. Metformin prevents fatty liver and improves balance of white/brown adipose in an obesity mouse model by inducing FGF21. Mediators Inflamm. 2016;2016:5813030.PubMedPubMedCentral
34.
Vieira JM, Norman S, Villa Del Campo C, et al. The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction. J Clin Invest. 2018;128(8):3402–12.PubMedPubMedCentralCrossRef
35.
Koyanagi H, Nakayama Y, Yanagawa H. Lower level of serum potassium and higher level of C-reactive protein as an independent risk factor for giant aneurysms in Kawasaki disease. Acta Paediatr. 1998;87:32–6.PubMedCrossRef
36.
Su Y, Feng S, Luo L, Liu R, Yi Q, et al. Association between IL-35 and coronary arterial lesions in children with Kawasaki disease. Clin Exp Med. 2019;19(1):87–92.PubMedCrossRef
37.
Hulejová H, Andrés Cerezo L, Kuklová M, et al. Novel adipokine fibroblast growth factor 21 is increased in rheumatoid arthritis. Physiol Res. 2012;61(5):489–94.PubMed
38.
Lin Z, Zhou Z, Liu Y, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE. 2011;6(4):e18398.PubMedPubMedCentralCrossRef
39.
Li Y, Huang J, Jiang Z, Jiao Y, Wang H. FGF21 inhibitor suppresses the proliferation and migration of human umbilical vein endothelial cells through the eNOS/PI3K/AKT pathway. Am J Transl Res. 2017;9(12):5299–307.PubMedPubMedCentral
40.
Yan J, Wang J, Huang H, et al. Fibroblast growth factor 21 delayed endothelial replicative senescence and protected cells from H2O2-induced premature senescence through SIRT1. Am J Transl Res. 2017;9(10):4492–501.PubMedPubMedCentral
41.
Si F, Wu Y, Gao F, Feng S, Liu R, Yi Q. Relationship between IL-27 and coronary arterial lesions in children with Kawasaki disease. Clin Exp Med. 2017;17(4):451–7.PubMedCrossRef
42.
Ong KL, Januszewski AS, O’Connell R, et al. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015;58(3):464–73.PubMedCrossRef
43.
Takeda Y, Fujita S, Ikemoto T, et al. The relationship of fibroblast growth factors 21 and 23 and α-Klotho with platelet activity measured by platelet volume indices. Clin Chem Lab Med. 2015;53(10):1569–74.PubMedCrossRef
Metadata
Title
Increased levels of circulating fibroblast growth factor 21 in children with Kawasaki disease
Authors
Yue Peng
Qiongfei Pei
Siqi Feng
Ya Su
Ruixi Liu
Qijian Yi
Pengfei Guo
Publication date
01-11-2019
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 4/2019
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-019-00577-4

Other articles of this Issue 4/2019

Clinical and Experimental Medicine 4/2019 Go to the issue

Original Article

IL-8 gene locus is associated with risk, severity and 28-day mortality of sepsis in a Chinese population

Original Article

Crescent lesions are not a predictive factor in adult-onset Henoch–Schönlein purpura nephritis

Original Article

NK and NKT-like cells in granulomatous and fibrotic lung diseases

Original Article

Severe thrombocytopenia in pregnancy: a case series from west China

Original Article

MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma

Review Article

Radiation-induced lung injury: latest molecular developments, therapeutic approaches, and clinical guidance
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits